NCT05529316Phase 2Terminated

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Study sponsor: Agenus Inc. · AGEN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-04-27Actual
Enrollment · participants150Actual
Source updated2026-10-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Objective Response Rate Description: Objective response rate will be determined using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Time frame: First dose through up to 3 months. After: Measure: Objective Response Rate Description: Objective response rate will be determined using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Time frame: Up to 40 months.

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Feb 2028. After: 27 Apr 2026.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

· 1 field changed

Actual enrollment decreased by 24 participants

Before: 174 participants (actual). After: 150 participants (actual).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview